International Journal of Clinical Research

Objective This study was to evaluate the efficacy of nimodipine combined with rosuvastatin calcium in the treatment of hypertensive intracerebral hemorrhage (HICH). Methods In December 2023, 100 patients with HICH in neurosurgery department of our hospital were selected and divided into two groups according to random number table: control group and observation group, each containing 50 cases. The control group was treated with conventional treatment combined with nimodipine, and the observation group was treated with rosuvastatin calcium on the basis of control group. The treatment period was 14 days. By comparing the hematoma volume, edema volume, NIHSS and ADL scores, superoxide dismutase and malondialdehyde levels before and after treatment, as well as adverse reactions and prognostic outcomes, the efficacy of the two treatment regimens was evaluated. Results The total effective rate of observation group was higher than that of control group (P < 0.05). After 14 days of treatment, the hematoma volume and edema volume in the observation group were significantly lower than those in the control group, the NIHSS score was significantly lower, the ADL score was significantly higher, the SOD level was increased, and the MDA level was decreased (P < 0.05). In addition, the mild disability rate in the observation group was higher than that in the control group, and the severe disability rate was lower than that in the control group (P < 0.05). Conclusion Nimodipine combined with rosuvastatin calcium has excellent efficacy in the treatment of HICH, can accelerate the reduction of hematoma and edema, optimize neurological function, reduce oxidative stress level, and is safe, worthy of promotion.

Nimodipine; Rosuvastatin calcium; Hypertensive cerebral hemorrhage; The amount of hematoma; Edema volume